This article is from: baltimoreravens.com
(Reuters) – Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Beqvez was approved in the U.S. last year, for the treatment of adults with moderate to severe hemophilia B.
(Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona)
Brought to you by www.srnnews.com
